Metsera Secures $215 Million Series B Funding Following Promising Phase 1 Weight Loss Data

Funding Amount:
Metsera has raised $215 million in a Series B funding round12.

Purpose:
The funding will be used to advance Metsera's obesity treatment pipeline, focusing on NuSH peptides3.

Clinical Background:
The funding follows the release of promising Phase 1 weight loss data, indicating the potential of Metsera's therapeutic approach12.

Market Context:
The funding reflects continued enthusiasm for GLP-1 drugs and innovative obesity therapies2.

Date:
The funding was announced on November 13, 202412.

Sources:

1. https://biotechjobs.io/2024/11/13/high-flying-metsera-follows-phase-1-weight-loss-data-with-215m-series-b-raise/

2. https://www.fiercebiotech.com/biotech/metsera-follows-phase-1-weight-loss-data-215m-series-b

3. https://biohackers.media/metsera-secures-215m-for-innovative-obesity-therapies/